Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522235 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01522235 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT01522235, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to see if administering intravenous immune globulin (IVIG) (putting immune globulin directly into your blood) helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality of life in men and women who have autoimmune autonomic ganglionopathy (AAG).
Interventions
- DRUG Double blinded IVIg
- OTHER Double blinded Placebo
- OTHER Single Blinded IVIg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522235
The ClinicalTrials.gov registry entry for NCT01522235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Double blinded IVIg is the first listed.
NCT01522235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522235 about?
NCT01522235 is a clinical study titled "Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy". The purpose of the study is to see if administering intravenous immune globulin (IVIG) (putting immune globulin directly into your blood) helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality of life in men and women who have aut...
What is the current status of trial NCT01522235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2012-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01522235?
The interventions under investigation include: Double blinded IVIg (DRUG), Double blinded Placebo (OTHER), Single Blinded IVIg (OTHER).
Who is sponsoring clinical trial NCT01522235?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.